ストックスクリーナーアプリを入手
175.42
4.75%
-8.75
前日終値:
$184.17
開ける：
$183.81
24時間の取引高:
1.22M
Relative Volume:
0.86
時価総額：
$11.14B
収益：
$763.34M
当期純損益:
$51.40M
株価収益率:
193.11
EPS:
0.9084
ネットキャッシュフロー:
$104.46M
1週間 パフォーマンス:
+0.89%
1か月 パフォーマンス:
+1.45%
6か月 パフォーマンス:
+38.03%
1年 パフォーマンス:
+13.50%
1日の値動き範囲:
$172.39
$186.00
1週間の範囲:
$169.73
$186.00
52週間の値動き範囲:
$100.99
$198.87
Repligen Corp Stock (RGEN) Company Profile
Compare RGEN vs ISRG, BDX, RMD, ALC, MDLN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
175.42 | 11.14B | 763.34M | 51.40M | 104.46M | 0.9084 |
ISRG
Intuitive Surgical Inc
|
426.70 | 150.74B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
191.75 | 52.23B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
238.97 | 33.61B | 5.54B | 1.52B | 1.74B | 10.37 |
ALC
Alcon Inc
|
66.18 | 31.99B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
35.96 | 31.55B | 29.14B | 1.07B | 1.05B | 1.1956 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-09-09 | 再開されました | UBS | Buy |
| 2026-07-07 | アップグレード | The Benchmark Company | Hold → Buy |
| 2026-06-02 | 再開されました | Wolfe Research | Outperform |
| 2026-05-15 | 再開されました | RBC Capital Mkts | Outperform |
| 2026-04-17 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-10-01 | 開始されました | HSBC Securities | Buy |
| 2025-09-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2025-07-22 | 再開されました | Stephens | Overweight |
| 2025-06-24 | 開始されました | Barclays | Overweight |
| 2025-04-29 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 開始されました | Evercore ISI | In-line |
| 2025-02-10 | 開始されました | TD Cowen | Buy |
| 2024-12-17 | 開始されました | Canaccord Genuity | Hold |
| 2024-11-14 | 開始されました | Wolfe Research | Peer Perform |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-26 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-06-18 | 開始されました | Guggenheim | Neutral |
| 2023-12-04 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-07-20 | 開始されました | Wells Fargo | Overweight |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-03-28 | 開始されました | The Benchmark Company | Buy |
| 2022-12-14 | 開始されました | Deutsche Bank | Hold |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2022-07-20 | 開始されました | UBS | Buy |
| 2021-10-14 | 開始されました | Exane BNP Paribas | Outperform |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2020-08-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-23 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-15 | 開始されました | Stifel | Buy |
| 2019-11-01 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2019-10-15 | 開始されました | SVB Leerink | Outperform |
| 2019-08-28 | 繰り返されました | First Analysis Sec | Outperform |
| 2019-08-23 | 再開されました | Stephens | Overweight |
| 2019-07-22 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2018-12-17 | アップグレード | CL King | Neutral → Buy |
| 2018-11-12 | ダウングレード | CL King | Buy → Neutral |
| 2018-09-26 | 開始されました | H.C. Wainwright | Neutral |
| 2017-12-08 | 開始されました | Citigroup | Buy |
| 2017-12-05 | 開始されました | JP Morgan | Overweight |
| 2017-11-13 | 開始されました | CL King | Buy |
| 2017-10-02 | アップグレード | First Analysis Sec | Equal-Weight → Overweight |
| 2017-07-21 | 開始されました | William Blair | Outperform |
| 2017-02-13 | アップグレード | Piper Jaffray | Neutral → Overweight |
すべてを表示
Repligen Corp (RGEN) 最新ニュース
Repligen to Report Third Quarter 2026 Financial Results - Yahoo Finance
Form 144 REPLIGEN CORP For: 12 October By Investing.com - Investing.com Canada
RGEN5964422 Bond Profile: Coupon and Redemption - TradingView
Repligen Corp (BSP:R2GE34) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Is It Too Late to Buy Repligen Corp (RGEN) After 6.1% Rally? GF Value Says Undervalued - GuruFocus
Repligen Corp (RGEN) Insider Trading Activity | Apple Insider Buys and Sells - GuruFocus
Repligen Corporation (RGEN) Stock Forecasts - Yahoo Finance
A 700-share stock grant joins options with a $174.86 exercise price for Repligen (RGEN)’s chief product officer. - Stock Titan
Repligen Corp at Leerink Global Healthcare Conference Transcript - GuruFocus
One holder reports no voting power in Repligen (RGEN), despite a 7.36M-share passive stake. - Stock Titan
Repligen CEO Olivier Loeillot sells $1.03m of company stock By Investing.com - Investing.com Nigeria
Repligen Corp (RGEN) CEO Olivier Loeillot Sells 5,535 Shares - GuruFocus
Repligen Corp (RGEN) Shares Fall 7.7% -- What GF Score of 85 Tel - GuruFocus
Repligen CEO Olivier Loeillot sells $1.03m of company stock - Investing.com
Repligen (RGEN) CEO sells shares at $190 and $178.75 under a preset trading plan. - Stock Titan
Repligen Closes BioLife Solutions Acquisition - Yahoo Finance
Repligen completes acquisition of BioLife Solutions - Investing.com
18 commercially approved therapies are supported by BioLife's cell-preserving media. Repligen completed the deal. - stocktitan.net
Repligen Completes Acquisition of BioLife Solutions - Yahoo Finance
Form 144 REPLIGEN CORP For: 5 October By Investing.com - Investing.com South Africa
Repligen Corp (RGEN) Stock Up 4.3% but GF Value Says Overvalued -- GF Score: 85/100 - GuruFocus
Loeillot proposes selling 4,202 Repligen (RGEN) shares through Fidelity. - stocktitan.net
For stock-grant taxes, Repligen (RGEN) withholds 1,248 CEO shares at $181.70 each. - stocktitan.net
Form 144 REPLIGEN CORP For: 5 October By Investing.com - Investing.com Nigeria
1,333 shares vested October 2 are proposed for sale at Repligen (NASDAQ: RGEN). - stocktitan.net
BioLife Solutions Shareholders Approve Repligen Merger Agreement - Yahoo Finance
REPLIGEN CORP. R (RGN.MU) Q1 FY2026 earnings call transcript - Yahoo Finance
Repligen Corporation (RGEN) Options Chain - Yahoo! Finance Canada
Repligen Corporation (RGEN) Options Chain - Yahoo! Finance Canada
A Look at Repligen Corp (RGEN) After 7.8% Decline -- GF Value $1 - GuruFocus
Continuous Bioprocessing Technologies MarketGlobal Forecast 2026-2031 | Market to Reach USD 8.5 Billion as Automation and Biologics Demand Fuel 12.1% CAGR - GlobeNewswire Inc.
Repligen stock price target reaffirmed at $225 by UBS on growth outlook - Investing.com South Africa
Repligen stock price target reaffirmed at $225 by UBS on growth outlook - Investing.com UK
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs? - TradingView
After a stock-unit release, Repligen (RGEN) withheld 421 shares from its CFO to cover taxes. - Stock Titan
Repligen CEO Olivier Loeillot sells $976,680 in company stock - Investing.com
Repligen CEO Loeillot sells $2.46m in shares - Investing.com
Repligen Corp (RGEN) CEO Olivier Loeillot Sells 12,946 Shares - GuruFocus
Repligen (RGEN) CEO sells shares at $190 each after exercising options under a trading plan. - Stock Titan
Form 144 REPLIGEN CORP For: 24 September By Investing.com - Investing.com Nigeria
Repligen Corporation (RGEN) Stock Forecasts - finance.yahoo.com
Is Repligen Corp (RGEN) Overvalued After 3.3% Rally? GF Value Sa - GuruFocus
Shares valued at $2.46 million are listed for sale by a Repligen (NASDAQ: RGEN) officer and director. - Stock Titan
Repligen Corp Stock Baskets - GuruFocus
Repligen Corp (BSP:R2GE34) Stock Price & 30 Year Financial Data - GuruFocus
Repligen Corporation stock hits 52-week high at 188.95 USD - Investing.com
Repligen Corporation stock hits 52-week high at 188.95 USD By Investing.com - Investing.com UK
Repligen Corp (RGEN) CEO Olivier Loeillot Sells 5,426 Shares - GuruFocus
Repligen Corp (RGEN) Stock Up 3.3% but GF Value Says Overvalued -- GF Score: 87/100 - GuruFocus
Repligen (RGEN) CEO sells 5,426 shares under plan - Stock Titan
Repligen Corp (RGEN) 財務データ
収益
当期純利益
現金流量
EPS
Repligen Corp (RGEN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Loeillot Olivier | Officer |
Oct 05 '26 |
Proposed Sale |
190.00 |
4,202 |
798,380 |
0 |
| Loeillot Olivier | Chief Executive Officer |
Oct 05 '26 |
Sale |
187.29 |
5,535 |
1,036,654 |
45,788 |
| Loeillot Olivier | Officer |
Oct 05 '26 |
Proposed Sale |
178.75 |
1,333 |
238,274 |
0 |
| Loeillot Olivier | Chief Executive Officer |
Sep 24 '26 |
Sale |
190.00 |
12,946 |
2,459,740 |
48,369 |
| Loeillot Olivier | Chief Executive Officer |
Sep 24 '26 |
Option Exercise |
155.11 |
12,946 |
2,008,020 |
56,773 |
| Loeillot Olivier | Officer |
Sep 24 '26 |
Proposed Sale |
190.00 |
12,946 |
2,459,740 |
0 |
| Loeillot Olivier | Chief Executive Officer |
Sep 21 '26 |
Sale |
180.00 |
5,426 |
976,680 |
48,369 |
| Loeillot Olivier | Chief Executive Officer |
Sep 21 '26 |
Option Exercise |
141.79 |
5,426 |
769,353 |
53,795 |
| Loeillot Olivier | Officer |
Sep 21 '26 |
Proposed Sale |
180.00 |
5,426 |
976,680 |
0 |
| Loeillot Olivier | Chief Executive Officer |
Sep 04 '26 |
Sale |
165.90 |
3,035 |
503,506 |
48,369 |
2.05%
1.36%
大文字化:
|
ボリューム (24 時間):